A Study of Pembrolizumab and Ipilimumab

Status: open

18-004 - Phase II study of pembrolizumab and ipilimumab following initial anti-PD1/L1 antibody

Treatment for Melanoma

Contact Us Or call (251) 445-9834


Phase II study evaluating the benefit of the combination of anti-PD1 (pembrolizumab) and anti-CTLA4 (ipilimumab) antibodies in advanced melanoma. The study will determine the response rate of the combination and evaluate other clinical parameters such as progression-free survival and safety of the combination following anti-PD1/L1 antibody. The study will also provide the opportunity to investigate blood or tumor based factors that may predict response to anti-PD1 antibody in combination with anti-CTLA4. IRB Number 18-004


This trial is sponsored by University of Chicago.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.